Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 3 Long-term Study to Evaluate the Safety and Efficacy of MND-2119 in Patients With Hypertriglyceridemia

NCT04221217 is registered in ClinicalTrials.gov with Mochida Pharmaceutical Company, Ltd. as lead sponsor.

NCT NCT04221217
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04221217 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 3 Long-term Study to Evaluate the Safety and Efficacy of MND-2119 in Patients With Hypertriglyceridemia
Lead sponsor
Mochida Pharmaceutical Company, Ltd.
Phase
Phase 3
Overall status
Completed
Start date
February 14, 2020
Completion date
July 14, 2021
Enrollment
120 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hypertriglyceridemia